Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 5/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546337 | 0.84 | FBP1 (0.48) | FBP1GAAKDM5BCDC7DBF4 | |
| SCHEMBL16273540 | 0.80 | FBP1 (0.49) | FBP1PTGDR2GAAMEN1KMT2A | |
| SCHEMBL25558476 | 0.74 | FBP1 (0.48) | FBP1GAAMEN1KMT2AMAPT | |
| SCHEMBL23793002 | 0.74 | FBP1 (0.44) | FBP1PTGDR2GAAMEN1KMT2A | |
| SCHEMBL25556546 | 0.72 | FBP1 (0.42) | FBP1CYP2A6MEN1KMT2AMAPT | |
| SCHEMBL25558445 | 0.71 | FBP1 (0.43) | FBP1PTGDR2MAPTLMNA | |
| SCHEMBL25556541 | 0.71 | MAPT (0.65) | FBP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL25556412 | 0.71 | LMNA (0.54) | FBP1PTGDR2MEN1KMT2AMAPT | |
| SCHEMBL25556360 | 0.69 | PTGS2 (0.56) | FBP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL25556449 | 0.69 | MEN1 (0.47) | FBP1GAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | FBP1 735/4885PTGDR2 4804/4885GAA 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.